Robin Jones to Neoplasms
This is a "connection" page, showing publications Robin Jones has written about Neoplasms.
Connection Strength
3.427
-
Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours. Eur J Cancer. 2019 10; 120:132-139.
Score: 0.533
-
Trends in Modern Phase 1 Oncology Trials. N Engl J Med. 2018 09 20; 379(12):1188-9.
Score: 0.498
-
Q-TWiST: What really matters to the cancer patient? Cancer. 2017 06 15; 123(12):2200-2202.
Score: 0.448
-
A phase I open-label trial evaluating the cardiovascular safety of regorafenib in patients with advanced cancer. Cancer Chemother Pharmacol. 2015 Oct; 76(4):777-84.
Score: 0.402
-
Cardio-oncology: a special focus issue from Future Oncology. Future Oncol. 2015; 11(14):1993-4.
Score: 0.385
-
Success is not final and failure is not fatal. J Clin Oncol. 2014 Oct 20; 32(30):3449-50.
Score: 0.377
-
Phase I study of intermittent oral dosing of the insulin-like growth factor-1 and insulin receptors inhibitor OSI-906 in patients with advanced solid tumors. Clin Cancer Res. 2015 Feb 15; 21(4):693-700.
Score: 0.377
-
Cardiac and cardiovascular toxicity of nonanthracycline anticancer drugs. Expert Rev Anticancer Ther. 2006 Sep; 6(9):1249-69.
Score: 0.216
-
First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1. Clin Cancer Res. 2019 10 01; 25(19):5808-5817.
Score: 0.131
-
Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicity. Expert Rev Cardiovasc Ther. 2008 Nov; 6(10):1311-7.
Score: 0.063